ImmunityBio Partners With Accord Healthcare To Expand ANKTIVA Access Across Europe Also Establishes Irish Subsidiary

ImmunityBio, Inc. has entered into a partnership with Accord Healthcare to expand patient access to ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) across Europe. The therapy is indicated for eligible patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), with or without papillary disease. In addition, ImmunityBio has established a new subsidiary in Dublin, Ireland, to strengthen its European distribution and commercialisation operations.

“Our partnership with Accord marks a significant step in our European growth strategy and our mission to redefine cancer care,” said Richard Adcock, President and CEO of ImmunityBio. “Accord’s scale, oncology leadership, and commercial reach support our goals to broaden patient access to ANKTIVA and unlock its full commercial potential in Europe.”

Under the agreement, Accord Healthcare will deploy a dedicated team of more than 100 sales, medical, and marketing professionals to support the launch and commercialisation of ANKTIVA throughout the United Kingdom, the European Union, and the European Free Trade Association (EFTA) countries of Iceland, Liechtenstein, and Norway. The collaboration is designed to accelerate market access and ensure the broad availability of the therapy for eligible patients.

“Our partnership with ImmunityBio reflects our shared commitment to expanding access to innovative cancer therapies for patients in Europe,” said Paul Tredwell, Global CEO at Accord Healthcare. “ANKTIVA represents an important advancement for eligible patients with BCG-unresponsive NMIBC CIS, and we are pleased to support its introduction across our markets.”

ANKTIVA in combination with BCG is now authorised in four major regulatory jurisdictions covering 33 countries. These include approval from the U.S. Food and Drug Administration in April 2024, approval from the Medicines and Healthcare Products Regulatory Agency in July 2025, accelerated approval from the Saudi Food and Drug Authority in January 2026, and a conditional marketing authorisation granted by the European Commission in February 2026. The European approval covers all 27 EU member states, as well as Iceland, Liechtenstein, and Norway.

“With approvals now spanning 33 countries, ImmunityBio has expanded global access to ANKTIVA for those with BCG-unresponsive NMIBC CIS, with or without papillary disease,” said Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio. “The 71% complete response rate and the durability of those responses support ANKTIVA’s role as a foundational backbone of next-generation immunotherapy for bladder cancer. Our goal is to further broaden access by rapidly completing the randomised trial in patients with BCG-naïve disease. In parallel, we have submitted our response to the U.S. FDA’s request for additional data related to BCG-unresponsive papillary-only NMIBC, and we await the Agency’s review.”